United Therapeutics Q3 Revenue Rises 4% as Net Income Falls 24%

RBC Capital increased its price target for United Therapeutics to $725, up from $697, while maintaining an Outperform rating. This target suggests a 19.1% upside from the Nov 4 close of $608.49. Recent analyst price targets for the company range from $695 to $768.

United Therapeutics reported Q3 revenue of $832.5M, up 4% YoY, beating estimates. Net income fell 24% to $258.6M due to higher R&D costs. Tyvaso DPI sales grew 13%. The company agreed to pay $525M to Pfizer's Arena unit to end royalties on ralinepag. Shares rose 5.9% post-results.

Wells Fargo raised its price target for United Therapeutics (UTHR) to $703, citing strong momentum and positive KOL feedback on TreSMI. The stock is near its 52-week high, with a 25% YTD return. Q3 revenue was $832.5M, beating estimates, but EPS missed. Tyvaso revenue grew 11% QoQ. Raymond James also raised its target to $720.

United Therapeutics (UTHR) reported record Q3 revenue of $833M, driven by Tyvaso's strong performance. Management highlighted growth opportunities, pipeline advancements, and intellectual property wins, but noted regulatory delays and supply chain concerns. Tyvaso revenue reached $504M, with increased patient starts and higher-dose adoption. The company expects future growth from nebulized Tyvaso and ralinepag.

United Therapeutics reported Q3 2026 revenue of $833 million, driven by Tyvaso demand. The company is expanding into cardiopulmonary and respiratory medicine, targeting 1 million patients. Management expects growth from Tyvaso and ralinepag, with 14 programs in development. Delays include the Soft Mist Inhaler NDA filing and API supplier compliance issues. The Liquidia settlement removes a competitor from the PH-ILD market, providing Tyvaso a growth opportunity.

United Therapeutics (UTHR) discussed Q3 earnings, noting a court decision upholding its IP and a settlement with Liquidia. The settlement removes PH-ILD from YUTREPIA's label. The company delayed its soft mist inhaler filing to 2027. UTHR is addressing FDA compliance issues for ralinepag and planning studies for ralinepag DPI. The FDA action date for oral ralinepag is June 24, 2027.